The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer
Aim: This study investigated the effect of neoadjuvant chemotherapy (NAC) on stromal tumor-infiltrating lymphocytes (sTILs) and their treatment response. Materials & methods: 115 patients with pre-NAC core biopsies and post-NAC surgical resection specimens were reviewed. Results: There was no significant change between pre- and post-treatment sTILs. Both pre- and post-NAC sTILs were significantly lower in patients with luminal A subtype. An increase in sTILs was observed in 21 (25.9%) patients after NAC, a decrease in 29 (35.8%) and no change in 31 (38.3%; p = 0.07). Pretreatment sTIL density was independent predictor of pathological complete response in multivariate analyses (odds ratio: 1.025, 95% CI: 1.003-1.047; p = 0.023). Conclusion: High sTIL density in core biopsies was independently related to pathological complete response. In addition, ER appears to be the most crucial factor determining the rate of sTIL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Future oncology (London, England) - 18(2022), 29 vom: 26. Sept., Seite 3289-3298 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ilgun, Ahmet Serkan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.10.2022 Date Revised 19.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fon-2022-0157 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345361342 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345361342 | ||
| 003 | DE-627 | ||
| 005 | 20231226024907.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2022-0157 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1151.xml |
| 035 | |a (DE-627)NLM345361342 | ||
| 035 | |a (NLM)36017739 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ilgun, Ahmet Serkan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.10.2022 | ||
| 500 | |a Date Revised 19.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: This study investigated the effect of neoadjuvant chemotherapy (NAC) on stromal tumor-infiltrating lymphocytes (sTILs) and their treatment response. Materials & methods: 115 patients with pre-NAC core biopsies and post-NAC surgical resection specimens were reviewed. Results: There was no significant change between pre- and post-treatment sTILs. Both pre- and post-NAC sTILs were significantly lower in patients with luminal A subtype. An increase in sTILs was observed in 21 (25.9%) patients after NAC, a decrease in 29 (35.8%) and no change in 31 (38.3%; p = 0.07). Pretreatment sTIL density was independent predictor of pathological complete response in multivariate analyses (odds ratio: 1.025, 95% CI: 1.003-1.047; p = 0.023). Conclusion: High sTIL density in core biopsies was independently related to pathological complete response. In addition, ER appears to be the most crucial factor determining the rate of sTIL | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a immune markers | |
| 650 | 4 | |a immunogenicity | |
| 650 | 4 | |a lymphocytic infiltrate, immune-cell infiltration | |
| 650 | 4 | |a neoadjuvant treatment | |
| 650 | 4 | |a pathologic complete response | |
| 650 | 4 | |a sTIL | |
| 650 | 4 | |a sTIL change | |
| 650 | 4 | |a tumor infiltrating lymphocyte | |
| 650 | 4 | |a tumor microenvironment | |
| 700 | 1 | |a Aktepe, Fatma |e verfasserin |4 aut | |
| 700 | 1 | |a Gonullu, Onur |e verfasserin |4 aut | |
| 700 | 1 | |a Kapucuoglu, Nilgun |e verfasserin |4 aut | |
| 700 | 1 | |a Yararbas, Kanay |e verfasserin |4 aut | |
| 700 | 1 | |a Alco, Gul |e verfasserin |4 aut | |
| 700 | 1 | |a Ozturk, Alper |e verfasserin |4 aut | |
| 700 | 1 | |a Elbuken Celebi, Filiz |e verfasserin |4 aut | |
| 700 | 1 | |a Erdogan, Zeynep |e verfasserin |4 aut | |
| 700 | 1 | |a Ordu, Cetin |e verfasserin |4 aut | |
| 700 | 1 | |a Unal, Caglar |e verfasserin |4 aut | |
| 700 | 1 | |a Duymaz, Tomris |e verfasserin |4 aut | |
| 700 | 1 | |a Soybir, Gursel |e verfasserin |4 aut | |
| 700 | 1 | |a Yavuz, Ekrem |e verfasserin |4 aut | |
| 700 | 1 | |a Tuzlali, Sitki |e verfasserin |4 aut | |
| 700 | 1 | |a Ozmen, Vahit |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology (London, England) |d 2005 |g 18(2022), 29 vom: 26. Sept., Seite 3289-3298 |w (DE-627)NLM161450725 |x 1744-8301 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:29 |g day:26 |g month:09 |g pages:3289-3298 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fon-2022-0157 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 29 |b 26 |c 09 |h 3289-3298 | ||